| ABSTRACT Objective:To evaluate the efficacy and safety of Qingkailing Injection (QKLI) for pneumonia.Methods:Randomized controlled trials (RCTs) regarding QKLI for the treatment of pneumonia were collected through searching in CNKI, VIP, WANFANG DATA, SinoMed, PubMed, Springer, Web of Science, Cochrane Central Register of Controlled Trials ，etc. Related RCTs were selected according to the inclusion and exclusion criteria. Then, extracting data and assessing the methodological quality of included studies by the Cochrane Collaboration’s tool for assessing risk of bias. Data analysis was conducted with Review Manager 5.3 and Stata 13.1 software. Results:17 RCTs involving 1 702 patients were included. Meta analysis and subgroup analysis showed, “QKLI+antibiotics+symptomatic treatment(ST)” group compared with “antibiotics+ST” group could improve the clinical total effective rate (RR=1.23, 95%CI: 1.14-1.33, P<0.000 01) and shorten the duration of fever (MD=-1.41, 95%CI:-1.60~-1.21, P<0.000 01); “QKLI+antibiotics+ST” group provided equally effect in the enhancement of clinical curative effect with “Ribavirin+antibiotics+ST” group, while there was no significant difference between the two groups (RR=1.09, 95%CI: 0.99-1.20, P=0.07). Moreover, QKLI could shorten the duration of cough and rale, and inhibit inflammatory reaction in patients with pneumonia. Additionally, 27 cases adverse drug reactions/adverse drug events (ADRs/ADEs) in experimental groups and 64 cases ADRs/ADEs in control groups were reported separately in 4 studies. There were no serious ADRs/ADEs reported. Conclusion:QKLI for the treatment of pneumonia could enhance the clinical total effective rate, shorten the duration of the main clinical signs and symptoms, and inhibit inflammatory reaction. However, there was no significant difference between the QKLI group and Ribavirin group in improving the total effective rate and no exact conclusion concluded on safety. |
